Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1548760

registered interest
date	06/12/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Asthma: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will make an assessment of the potential correlation between the capacity in the severe asthma centre network and levels of uptake of severe asthma biologics in England.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	104145
answer	answer is ministerial correction date of answer 12/12/2022 answer text <p>There are no plans to make a specific assessment. NHS England’s severe asthma collaborative is developing the capacity in severe asthma centres to streamline patient pathways for biologic therapy and reduce variation in prescribing and patient management. A toolkit has been produced to support clinical teams.</p> answering member constituency Faversham and Mid Kent answering member printed Helen Whately question first answered 12/12/2022 12:31:10 answering member 4527 label Biography information for Helen Whately
tabling member	4131 label Biography information for Jim Shannon

1457274

registered interest
date	14/04/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Asthma: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to the findings of LOGEX’s International Comparison Medicines Uptake 2021 report to NHS England & NHS Improvement, published in December 2021, what assessment his Department has made of the effect of the capacity available in the severe asthma centres on levels of uptake of severe asthma biologics.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	153958
answer	answer is ministerial correction date of answer 25/04/2022 answer text <p>No specific assessment has been made. NHS England and NHS Improvement’s Severe Asthma Collaborative are developing the capacity of the severe asthma centres to streamline patient pathways to biologic therapy and reduce variation in prescribing and patient management. A toolkit has been produced to support clinical teams.</p> answering member constituency Lewes answering member printed Maria Caulfield question first answered 25/04/2022 16:24:35 answering member 4492 label Biography information for Maria Caulfield
tabling member	4131 label Biography information for Jim Shannon

1456324

registered interest
date	31/03/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Asthma: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to the Government's 2019 Voluntary Scheme for Branded Medicines Pricing and Access, what progress the Government has made in respect of severe asthma in attaining its objective of reaching the upper quartile of uptake for the five highest health gain categories; what assessment he has made of the viability of retaining that objective in respect of severe asthma; and if he will make a statement.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	151109
answer	answer is ministerial correction date of answer 19/04/2022 answer text <p>NHS England and NHS Improvement commissioned LOGEX and IVM to report on the current usage of the five highest health gain categories against 10 other similar European countries to understand national and international differences. While the LOGEX and IVM report did not investigate the reasons for differences in use of asthma biologics, the report demonstrated that use of biologics in England is increasing. The National Institute for Health and Care Excellence’s recommendations include that physicians evaluate patients on biologics and halt treatment if the patient does not respond adequately.</p><p>The report suggests that variation in the use of biologics in the population in England reflects documented differences in clinical practice. NHS Digital’s innovation scorecard estimates report on the use of biologic medicines to treat severe asthma shows that the level of use in England is in line with the expectations of the National Institute for Health and Care Excellence’s recommendations. The Accelerated Access Collaborative has undertaken a review of the patient’s journey to the initiation of asthma biologic treatment in severe asthma centres. The findings are informing the development of a consensus clinical pathway for uncontrolled and severe asthma with recommended timelines and roles and responsibilities for healthcare professionals. The clinical pathway is due to be published shortly.</p> answering member constituency Lewes answering member printed Maria Caulfield grouped question UIN 151107 151108 question first answered 19/04/2022 15:16:49 answering member 4492 label Biography information for Maria Caulfield
tabling member	4131 label Biography information for Jim Shannon

1348832

registered interest
date	20/07/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Asthma: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what has been the effect of home delivery of biologic medication for asthma patients on patient outcomes.
tabling member constituency	Makerfield
tabling member printed	Yvonne Fovargue
uin	36618
answer	answer is ministerial correction date of answer 27/08/2021 answer text <p>No specific assessment has been made of the effect of home delivery of asthma biologic medication on patient outcomes.</p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 27/08/2021 10:41:59 answering member 4380 label Biography information for Jo Churchill
tabling member	4034 label Biography information for Yvonne Fovargue

1331943

registered interest
date	10/06/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Asthma: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of extending the NHS Accelerated Access Collaborative's (AAC) rapid uptake programme for asthma biologic therapies in response to the impact of the covid-19 outbreak on the work of the AAC.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	13948
answer	answer is ministerial correction date of answer 22/06/2021 answer text <p>The Department, the Association of the British Pharmaceutical Industry (ABPI) and NHS England and NHS Improvement set the objective of reaching the upper quartile of uptake in relation to comparator countries for the five highest health gain categories during the first half of the Voluntary Scheme for Branded Medicines Pricing and Access, which was published in 2019. This objective is not intended as a target for the prescription of medicines. Medicines prescribing, including the highest health gain categories, remains a decision between the clinician and patient in line with guidance and recommendations made by National Institute for Health and Care Excellence.</p><p>When selecting the countries for international comparison of uptake of the five highest health gain categories, NHS England and NHS Improvement looked for countries with similar health systems and populations to England. NHS England and NHS Improvement have commissioned an independent third party to develop an objective methodology to compare uptake rate between countries.</p><p>The Accelerated Access Collaborative (AAC) worked closely with NHS England and NHS Improvement in the identification of potential five highest health gain categories for support through its Rapid Uptake Products programme. Following the open selection process, asthma biologics were selected for tailored support to increase their adoption in the National Health Service for the treatment of severe asthma as part of the 2021/22 programme. The Academic Health Science Networks are also providing leadership and support to NHS organisations to implement changes to transform severe asthma services locally and improve access to these medicines. Support for the programme will continue to be kept under review.</p> answering member constituency Charnwood answering member printed Edward Argar grouped question UIN 13945 13946 13947 question first answered 22/06/2021 15:59:20 answering member 4362 label Biography information for Edward Argar
tabling member	4131 label Biography information for Jim Shannon

823588

registered interest
date	16/01/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Asthma: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will make an estimate of the average yearly cost to patients of paying for prescribed asthma medication.
tabling member constituency	Warrington North
tabling member printed	Helen Jones
uin	123051
answer	answer is ministerial correction date of answer 24/01/2018 answer text <p>The Department has made no such estimate. FP10 prescriptions forms do not specify what clinical indication the medicine/device is being prescribed for, therefore the requested data is not collected.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 24/01/2018 12:15:06 answering member 4067 label Biography information for Steve Brine
tabling member	432 label Biography information for Helen Jones

514073

registered interest
date	19/04/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Asthma: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, how much was spent by the NHS on asthma drugs in each year since 2010.
tabling member constituency	Halton
tabling member printed	Derek Twigg
uin	34586
answer	answer is ministerial correction date of answer 25/04/2016 answer text <p>Information on National Health Service expenditure on drugs for the treatment of asthma<sup>1</sup> in primary and secondary care is shown in the table.</p><p> </p><p>Since some drugs are prescribed to treat more than one condition and as the condition for which a drug is prescribed is not collected, it is not possible to specify the different conditions for which a drug may have been prescribed. The information provided may therefore include costs from the prescribing of drugs that treated conditions other than asthma.</p><p> </p><p> </p><table><tbody><tr><td colspan="4"><p>Cost of drugs for the treatment of asthma, England<sup>2</sup></p></td></tr><tr><td><p>Year</p></td><td><p>Primary care (£ millions)</p></td><td><p>Secondary care (£ millions)</p></td><td><p>Combined total (£ millions)</p></td></tr><tr><td><p>2010</p></td><td><p>952.4</p></td><td><p>43.9</p></td><td><p>999.3</p></td></tr><tr><td><p>2011</p></td><td><p>968.5</p></td><td><p>45.1</p></td><td><p>1,013.6</p></td></tr><tr><td><p>2012</p></td><td><p>1,007.5</p></td><td><p>49.0</p></td><td><p>1,056.5</p></td></tr><tr><td><p>2013</p></td><td><p>1,018.3</p></td><td><p>52.4</p></td><td><p>1,070.7</p></td></tr><tr><td><p>2014</p></td><td><p>1,031.2</p></td><td><p>56.1</p></td><td><p>1,087.2</p></td></tr><tr><td><p>2015 <sup>3</sup></p></td><td><p>1,039.4</p></td><td><p><strong>-</strong></p></td><td><p><strong>-</strong></p></td></tr></tbody></table><p> </p><p><em>Sources:</em> Prescription Cost Analysis (PCA) system data provided by the Health and Social Care Information Centre (primary care). Hospital Pharmacy Audit Index (HPAI) provided by IMS Health (secondary care).</p><p> </p><p><em>Notes:</em></p><p><sup>1 </sup>Drugs for the treatment of asthma have been defined as those included in the following British National Formulary (BNF) sections, using the classification system prior to edition 70:</p><p>3.1.1 Adrenoceptor agonists</p><p>3.1.2 Antimuscarinic bronchodilators</p><p>3.1.3 Theophylline</p><p>3.2 Corticosteroids</p><p>3.3.1 Cromoglicate and related therapy</p><p>3.3.2 Leukotriene receptor antagonists</p><p>3.4.2 Allergen immunotherapy (omalizumab only)</p><p><sup>2</sup> Cost of drugs at NHS list price not taking account of discounts, dispensing costs, fees or prescription charges income. Totals may not add up due to rounding.</p><p><sup>3</sup> Secondary care data for 2015 is not yet available.</p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 25/04/2016 13:04:35 answering member 4020 label Biography information for George Freeman
tabling member	429 label Biography information for Derek Twigg

386284

registered interest
date	29/06/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Asthma: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what assessment he has made of the cost effectiveness of prescribing medicines for asthma patients; and if he will make a statement.
tabling member constituency	South Down
tabling member printed	Ms Margaret Ritchie
uin	4661
answer	answer is ministerial correction date of answer 02/07/2015 answer text <p>We have made no such assessment. The National Institute for Health and Care Excellence (NICE) is responsible for providing guidance to the National Health Service on the clinical and cost effectiveness of selected drugs and indications through its technology appraisal programme. NICE has published several pieces of technology appraisal guidance covering a number of different technologies for use in the treatment of adults and children with asthma. Further information is available on NICE’s website at:</p><p> </p><p> </p><p> </p><p><a href="http://www.nice.org.uk/guidance/conditions-and-diseases/respiratory-conditions/asthma" target="_blank">www.nice.org.uk/guidance/conditions-and-diseases/respiratory-conditions/asthma</a></p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 02/07/2015 12:15:21 answering member 4020 label Biography information for George Freeman
tabling member	4130 label Biography information for Baroness Ritchie of Downpatrick

384473

registered interest
date	22/06/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Asthma: Drugs
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government what steps they are taking to ensure that patients with asthma receive the right medication.
tabling member printed	Lord Taylor of Warwick
uin	HL684
answer	answer is ministerial correction date of answer 29/06/2015 answer text <p>The NHS mandate for 2015-16 says that every patient with a long-term condition, including asthma and other respiratory conditions, should be offered a personalised care action plan. They and their families or carers should know the right medications to use at the right times and how to use them, and to understand the importance of monitoring their condition and how to do this.</p><p> </p> answering member printed Lord Prior of Brampton question first answered 29/06/2015 14:51:48 answering member 127 label Biography information for Lord Prior of Brampton
tabling member	1796 label Biography information for Lord Taylor of Warwick

381490

registered interest
date	16/06/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Asthma: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what discussions he has had with (a) the British Medical Association and (b) other medical bodies on possible adverse effects of the use of inhalers for the treatment of asthma.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	2670
answer	answer is ministerial correction date of answer 24/06/2015 answer text <p>There have been no recent discussions between the Secretary of State and the British Medical Association or other medical bodies on possible adverse effects of the use of inhalers for the treatment of asthma.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 24/06/2015 11:21:35 answering member 3918 label Biography information for Jane Ellison
tabling member	4131 label Biography information for Jim Shannon